CLINICAL TRIALS HAVE PROVEN THE EFFECTIVENESS OF NINTEDANIB TO TREAT A WIDE RANGE OF FIBROSING INTERSTITIAL LUNG DISEASE

Abstract

Nintedanib is a tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis. Its effectiveness has been proven in clinical trials. Still, there are more fibrosing interstitial lung diseases, but treatment options are limited. Because of the similarities in the pathophysiological processes of both idiopathic pulmonary fibrosis and a number of fibrosing interstitial lung diseases, preclinical and clinical studies have shown that nintedanib may be effective in a wide range of fibrosing interstitial lung diseases.